Reviva Shares Sink 41% After Proposed Offering To Fund Schizophrenia Trial

Shares of Reviva Pharmaceuticals plunged more than 42% overnight after the company announced a proposed public offering of common stock and warrants, with all securities to be sold by Reviva and A.G.P./Alliance Global named in the deal. The announcement triggered a sharp sell-off driven by dilution concerns; the article did not disclose offering size or pricing.

Analysis

Shares of Reviva Pharmaceuticals plunged more than 42% overnight after the company announced a proposed public offering of common stock and warrants, with all securities to be sold by Reviva and A.G.P./Alliance Global named in the deal. The announcement triggered a sharp sell-off driven by dilution concerns; the article did not disclose offering size or pricing.